Breaking News

Evotec Acquires Bionamics GmbH

By Kristin Brooks | March 24, 2014

Expands discovery pipeline in multiple sclerosis and CNS

Evotec AG has acquired Bionamics GmbH, an asset management company based in Germany that focuses on translating academic innovations into assets for the pharma and biopharma industry. Bionamics brings a portfolio of fully funded projects including focus areas in neurodegeneration and CNS. Evotec has acquired all shares of Bionamics for cash and future milestone payments. Financial details were not disclosed.
Dr. Timm Jessen has been appointed executive vice president of business development for the company’s “EVT Innovate" strategy and will work to enhance translation capabilities.
Dr. Werner Lanthaler, chief executive officer of Evotec, said, "With the acquisition of Bionamics we accelerate our EVT Innovate strategy and enlarge our reach towards outstanding innovations. We welcome the openness of Bionamics to join the discovery infrastructure of Evotec. We are also very happy to welcome Dr. Timm Jessen back at Evotec. In his new management role, Dr. Jessen will be responsible for the commercialization of "EVT Innovate" projects."
Dr. Timm Jessen, managing director of Bionamics GmbH, said, "We highly value Evotec's strategic appreciation of our work and its success as demonstrated e.g. in managing the NEU² program, a consortium of academic, biotech and Pharma partners focusing on novel products to treat Multiple Sclerosis and other neurodegenerative diseases. The combination of our management skills with Evotec's strong operational capabilities offers a unique constellation for researchers and entrepreneurs around the globe to accelerate their innovation together with us. I very much look forward to expand this concept further within the Evotec Group."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important